Home Stock US NIH launches long-COVID trials of Pfizer’s Paxlovid, different therapies By Reuters

US NIH launches long-COVID trials of Pfizer’s Paxlovid, different therapies By Reuters

0
US NIH launches long-COVID trials of Pfizer’s Paxlovid, different therapies By Reuters

[ad_1]

5/5

© Reuters. FILE PHOTO: Pfizer’s coronavirus illness (COVID-19) tablet Paxlovid is manufactured in Ringaskiddy, Eire on this undated picture obtained by Reuters on November 16, 2021. Pfizer/Handout by way of REUTERS/File Photograph

2/5

(Reuters) – The U.S. Nationwide Institutes of Well being (NIH) stated on Monday that it had launched mid-stage scientific trials to check at the least 4 remedies, together with Pfizer (NYSE:)’s Paxlovid, in sufferers with signs of lengthy COVID.

The research are designed to guage a number of therapies, the place the primary a part of trial will check an extended dosing routine of the antiviral COVID-19 drug Paxlovid to see if it improves lengthy COVID signs.

The advanced medical situation entails greater than 200 signs starting from exhaustion and cognitive impairment to ache, fever and coronary heart palpitations that may final for months and even years following a COVID-19 an infection.

NIH stated different elements of the research may even check for mind fog and reminiscence issues associated signs.

It can use medical remedies like a web-based mind coaching program referred to as BrainHQ by San Franscisco-based non-public firm Posit Science Corp and Soterix Medical Inc’s gadget that makes use of a small electrical present to stimulate mind exercise, the well being company added.

Extra scientific trials are anticipated to be launched to check not lower than seven extra remedies, it stated.

[ad_2]

LEAVE A REPLY

Please enter your comment!
Please enter your name here